Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
1995-7-14
pubmed:abstractText
1. The alpha 1-adrenoceptor subtypes of rat heart were characterized in binding experiments performed with [3H]-prazosin as the radiolabel. The specific binding to the alpha 1-adrenoceptors was determined with 0.3 microM prazosin, because phentolamine (10 microM) was insufficient to inhibit completely the specific binding of high concentrations of [3H]-prazosin. 2. In saturation experiments, [3H]-prazosin bound to two distinct affinity sites (pKD = 10.39 and 8.19). The proportion of the low affinity sites was approximately 84% of total specific binding. Membranes pretreated with chloroethylclonidine (CEC, 10 microM) also showed two distinct affinity sites for [3H]-prazosin, although the maximum numbers of high and low affinity sites were reduced by 86 and 64%, respectively. 3. In competition experiments, [3H]-prazosin (100 pM) binding was inhibited by WB4101 (2-(2,6-dimethoxy-phenoxyethyl)aminomethyl-1,4-benzodioxane) and 5-methylurapidil. The inhibition curves displayed shallow slopes which could be subdivided into high and low affinity components (pKi = 10.43 and 8.36 for WB4101, 8.62 and 6.61 for 5-methylurapidil). However, unlabelled prazosin or HV723 (alpha-ethyl-3,4,5-trimethoxy-alpha-(3-((2-(2-methoxyphenoxy)-ethyl)amin o) propyl)benzeneacetonitrile fumarate) competed for [3H]-prazosin binding monophasically (pKi = 10.34 and 8.28, respectively). In CEC-pretreated membranes, prazosin, WB4101, 5-methylurapidil and HV723 antagonized the [3H]-prazosin (100 pM) binding monophasically (pKi = 9.70, 9.56, 8.60 and 8.82, for each antagonist). 4. On the other hand, 1000 pM [3H]-prazosin binding was inhibited by unlabelled prazosin biphasically (pKi = 10.49 and 8.49). HV723 did not discriminate both prazosin-high and low affinity sites (pKi = 8.18). 5. These results suggest the presence of at least three distinct alpha1-adrenoceptor subtypes in rat hearts(two prazosin-high affinity sites and one prazosin-low affinity site). According to the recent alpha l-adrenoceptor subclassifications, one of the former two sites corresponds to the alpha 1B subtype with low affinities for WB4101 and 5-methylurapidil and sensitive to CEC, while another site with relatively high affinities for WB4101 and 5-methylurapidil may be classical alpha 1A, cloned alpha 1c, alpha 1D subtypes or their mixture. The prazosin-low affinity site corresponds to putative alpha 1L subtype with low affinity for HV723,which may be predominantly involved in the positive inotropic response to phenylephrine.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/7780636-1354902, http://linkedlifedata.com/resource/pubmed/commentcorrection/7780636-1359975, http://linkedlifedata.com/resource/pubmed/commentcorrection/7780636-1361871, http://linkedlifedata.com/resource/pubmed/commentcorrection/7780636-1657194, http://linkedlifedata.com/resource/pubmed/commentcorrection/7780636-1661838, http://linkedlifedata.com/resource/pubmed/commentcorrection/7780636-1687370, http://linkedlifedata.com/resource/pubmed/commentcorrection/7780636-1706716, http://linkedlifedata.com/resource/pubmed/commentcorrection/7780636-1970493, http://linkedlifedata.com/resource/pubmed/commentcorrection/7780636-1970822, http://linkedlifedata.com/resource/pubmed/commentcorrection/7780636-2442626, http://linkedlifedata.com/resource/pubmed/commentcorrection/7780636-2569345, http://linkedlifedata.com/resource/pubmed/commentcorrection/7780636-2827909, http://linkedlifedata.com/resource/pubmed/commentcorrection/7780636-2845398, http://linkedlifedata.com/resource/pubmed/commentcorrection/7780636-2890094, http://linkedlifedata.com/resource/pubmed/commentcorrection/7780636-3010073, http://linkedlifedata.com/resource/pubmed/commentcorrection/7780636-3022607, http://linkedlifedata.com/resource/pubmed/commentcorrection/7780636-6126793, http://linkedlifedata.com/resource/pubmed/commentcorrection/7780636-6254391, http://linkedlifedata.com/resource/pubmed/commentcorrection/7780636-7902286, http://linkedlifedata.com/resource/pubmed/commentcorrection/7780636-7911718, http://linkedlifedata.com/resource/pubmed/commentcorrection/7780636-7916507, http://linkedlifedata.com/resource/pubmed/commentcorrection/7780636-7938162, http://linkedlifedata.com/resource/pubmed/commentcorrection/7780636-8097950, http://linkedlifedata.com/resource/pubmed/commentcorrection/7780636-8103925, http://linkedlifedata.com/resource/pubmed/commentcorrection/7780636-8183249, http://linkedlifedata.com/resource/pubmed/commentcorrection/7780636-8185565, http://linkedlifedata.com/resource/pubmed/commentcorrection/7780636-8312131, http://linkedlifedata.com/resource/pubmed/commentcorrection/7780636-942051
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
0007-1188
pubmed:author
pubmed:issnType
Print
pubmed:volume
114
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1026-30
pubmed:dateRevised
2010-11-18
pubmed:meshHeading
pubmed:year
1995
pubmed:articleTitle
Pharmacological characterization of alpha 1-adrenoceptor subtypes in rat heart: a binding study.
pubmed:affiliation
Second Department of Surgery, Fukui Medical School, Matsuoka, Japan.
pubmed:publicationType
Journal Article, In Vitro, Research Support, Non-U.S. Gov't